Pangu
Contact
Clinical Trials
Patients
Primary Menu
Skip to content
Company
About Us
Leadership Team
Board of Directors
Advisors
Contact
Our Science
tRNA SYNTHETASE BIOLOGY
Intellectual Property
Publications, Posters and Presentations
R&D
Pipeline
Efzofitimod
Research Programs
Pangu
Patients
Clinical Trials
About Pulmonary Sarcoidosis
EFZO-FIT
™
About SSc-ILD
EFZO-CONNECT
™
Expanded Access Policy
Careers
Working at aTyr
Career Opportunities
Investors and Media
News Releases
SEC Filings
Stock Information
Events and Webcasts
Investor Alerts
Corporate Governance
Analyst Coverage
Media
Treatment with ATYR1923 Reduces Biomarkers in COVID-19 Pneumonia
European Respiratory Society, 2021
«
Engineering an Anti-Neuropilin-2 (NRP2) Antibody that Selectively Blocks NRP2 Interactions with Semaphorin and Plexin
Immunomodulatory Protein ATYR1923 Disrupts an In-Vitro Model of Sarcoid Granuloma Formation
»
© 2007 - 2024 aTyr Pharma.
Legal
Privacy Policy
By continuing to browse this site, you agree to our
use of cookies
.
I understand
MENU
Company
About Us
Leadership Team
Board of Directors
Advisors
Contact
Our Science
Extracellular
t
RNA Synthetase Biology
Intellectual Property
Publications, Posters and Presentations
R&D
Pipeline
Efzofitimod
Research Programs
Pangu
Patients
Clinical Trials
About Pulmonary Sarcoidosis
EFZO-FIT
™
About SSc-ILD
EFZO-CONNECT
™
Expanded Access Policy
Careers
Career Opportunities
Working at aTyr
Investors and Media
Corporate Governance
Board of Directors
Board Committees
News Releases
SEC Filings
Stock Information
Analyst Coverage
Investor Alerts
Events and Webcasts
Media
Privacy Policy
